Key result
High-dose growth hormone increases LV mass index ~12% and induces concentric remodeling in healthy volunteers.
Why the study?
Does supraphysiological growth hormone administration alter cardiac morphology and function in young normal volunteers?
RCT (n=60)
Double-blind
randomized
Yes
Does supraphysiological growth hormone administration alter cardiac morphology and function in young normal volunteers?
Short-term administration of supraphysiological doses of growth hormone induces rapid concentric left ventricular remodeling and a high cardiac output state in normal young adults.
High-dose GH induces concentric LV remodeling and high cardiac output within 4 weeks in healthy volunteers; extends RCT evidence on short-term GH cardiotoxicity and cautions against doping.
GH is an agent widely used in sport to improve physical performance and has been proposed as adjunctive therapy in several clinical conditions. However, its short-term effects on the normal human heart are poorly understood. Sixty young normal volunteers (30 males and 30 females) were enrolled in a multicenter, double-blind, placebo-controlled study. All subjects were randomized to receive GH (0.03 or 0.06 mg/kg.d) or placebo. A complete Doppler-echocardiographic examination was performed at baseline and after 4 wk of treatment. Low-dose GH did not significantly affect echocardiographic parameters. In contrast, high-dose GH increased left ventricular mass index by 12% (P < 0.05). The type of growth response was concentric, because left ventricular wall thickness but not diameter increased, leading to a 10% increase of relative wall thickness. These structural changes were associated with functional changes, including a significant increase in cardiac index and a decrease in peripheral vascular resistance; diastolic function was not altered. Fractional shortening and systemic blood pressure were unchanged in the two treatment groups. In conclusion, administration of GH for 4 wk at doses that simulate GH abuse in sport caused a high cardiac output state associated with concentric left ventricular remodeling.
No takes yet. Share an insight, caveat, or question.
Cittadini et al. (2002) conducted an RCT in Healthy volunteers (n=60). Growth hormone (GH) vs. Placebo was evaluated on Echocardiographic parameters including left ventricular mass index (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: